Evidence map›Paper›PMID 35286515›Full record

ArticleNeurochemical research2022

Dose-Dependent Effects of Astaxanthin on Ischemia/Reperfusion Induced Brain Injury in MCAO Model Rat.

Forough Taheri, Ehsan Sattari, Maryam Hormozi, Hassan Ahmadvand, Mohammad Reza Bigdeli, Parastou Kordestani-Moghadam, Khatereh Anbari, Sara Milanizadeh, Mehrnoush Moghaddasi

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Forough TaheriRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Ehsan SattariRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.
Maryam HormoziRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.ORCID http://orcid.org/0000-0003-2793-1430
Hassan AhmadvandHepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.ORCID http://orcid.org/0000-0002-9406-3592
Mohammad Reza BigdeliFaculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Parastou Kordestani-MoghadamRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran.ORCID http://orcid.org/0000-0003-1251-2516
Khatereh AnbariCommunity Medicine Department, Lorestan University of Medical Sciences, Khorramabad, Iran.ORCID http://orcid.org/0000-0002-6468-3053
Sara MilanizadehFaculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Mehrnoush MoghaddasiRazi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran. m_moghaddasi@hotmail.com.ORCID http://orcid.org/0000-0003-2995-963X
Lorestan University of Medical Sciences · IRShahid Beheshti University · IRHamedan University of Medical Sciences · IR

Funding

Lorestan University of Medical Sciences A-10-1724-1
6 · The paper itself

Abstract

Excitotoxicity and oxidative stress are central to the pathology of the nervous system, and inhibition of excitotoxicity induced by glutamate is one of the therapeutic goals determined for stroke. The present study aimed to investigate the effects of Astaxanthin, a potent natural antioxidant, on complications caused by acute cerebral stroke. In this research, 60 male Wistar rats were used which were divided into 5 groups as follow: (1) the sham group (vehicle), (2) the ischemic control group (vehicle), and the ischemic groups treated by Astaxanthin with doses of 25, 45, and 65 mg/kg. In the ischemic groups, ischemic model was performed by middle cerebral artery occlusion (MCAO) method, and the Astaxanthin administration was carried out after the artery occlusion and before opening the artery. The obtained results indicated that Astaxanthin could significantly reduce stroke volume, neurological deficits, and lipid peroxidation. Moreover, it was able to restore total oxidant status (TOS) and caspase 3 level to the normal level. The activity of antioxidant enzyme glutathione peroxidase (GPX), and the expression of catalase, GPx and nuclear factor kappa B (NFκb) genes, which were reduced after ischemia, were increased. This phenomenon was particularly pronounced for glutamate transporter 1 (GLT-1). Furthermore, Astaxanthin decreased the augmented pro-apoptotic gene Bax and restored the reduced Bcl2 expression to the normal level. Significant effects on the P53 and PUMA expression were not observed. Overall, the medium dosage of Astaxanthin appears to be more effective in reducing the complications of ischemia, particularly on our major study endpoints (stroke volume and neurological defects). Longer studies with a more frequent administration of Astaxanthin are required to better understand the precise mechanism of Astaxanthin.

Indexed as

Brain InjuriesBrain IschemiaNeuroprotective AgentsReperfusion InjuryStrokeAnimalsAntioxidantsDisease Models, AnimalInfarction, Middle Cerebral ArteryMaleRatsRats, WistarReperfusionXanthophyllsAntioxidantsastaxanthineNeuroprotective AgentsXanthophyllsAstaxanthinGene expressionGlutamate transporterMiddle cerebral artery occlusionNeurological deficitStroke

Identifiers

PMID35286515
OpenAlexW4221079314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.